Teledyne FLIR Defense Wins $17.5 Million Contract from armasuisse to Deliver Black Hornet 4 Nano-Drones for Dismounted and Vehicle-Integrated Reconnaissance
2.2.2026 08:00:00 CET | Business Wire | Press Release
Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE:TDY), announced that it has received a $17.5 million contract from armasuisse, the Swiss Federal Office of Defence Procurement, to deliver a large number of Black Hornet® 4 Personal Reconnaissance Systems, one of the world’s most advanced and widely deployed nano-drones. Black Hornet 4 was selected as an airborne dismountable Intelligence, Surveillance, and Reconnaissance (ISR) capability sensor for armasuisse’s Piranha 8x8 Armored engineering vehicle program.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260201061637/en/
Teledyne FLIR Defense has won a $17.5 million contract from armasuisse, the Swiss Federal Office of Defence Procurement, to deliver a large number of Black Hornet® 4 Personal Reconnaissance Systems, one of the world’s most advanced and widely deployed nano-drones. Black Hornet 4 was selected as an airborne capability sensor for armasuisse’s Piranha 8x8 Armored engineering vehicle program. Black Hornet’s existing software is being modified to integrate with the Piranha’s digital infrastructure. Under the setup, the drone’s live video stream will be shared on vehicle displays and provide target data, coordinates, and other situational awareness to vehicle commanders and crew.
As part of the effort, Black Hornet’s existing software has been modified to be integrated with the Piranha’s digital infrastructure. Under the setup, the drone’s live video stream will be shared on vehicle displays and provide target data, coordinates, and other situational awareness to vehicle commanders and crew. The Black Hornet 4 will be integrated through harmonized military standards with the vehicles’ Integrated Combat Solution (ICS), provided by Kongsberg Defence & Aerospace.
Drone operators will be able to connect the Black Hornet control tablet to the vehicle ICS for either dismounted or mobile operations. After launching the UAV by hand out of the vehicle, operators can fly the Black Hornet on intelligence gathering missions while all data is simultaneously shared with the crew. Among its features, the Black Hornet can both receive waypoints from the ICS for further reconnaissance as well as generate target points that can be fed to the vehicle’s Remote Weapon Station. The solution is fully detachable during operations, so operators can dismount from the vehicle and reattach while the drone is flying.
“This first fielded-vehicle integration for the Black Hornet 4 highlights its unique tactical capabilities as a force multiplier,” said Dr. JihFen Lei, president of Teledyne FLIR Defense and senior vice president of Teledyne Technologies. “By providing the same immediate situational data to all vehicle systems and crew, we can help reduce cognitive burden and boost warfighting effectiveness.
“The armasuisse program shows the market potential for UAS integration on armored vehicles globally and the promise of ‘drone-in-a-box’ systems FLIR Defense has developed specifically for vehicles, including our Black Recon™ and SkyCarrier™ solutions,” Lei added.
Black Hornet 4 represents the next generation of lightweight nano-drones, able to provide enhanced day/night covert situational awareness to small fighting units. Its 12-megapixel daytime camera and high-resolution thermal imager deliver crisp video and still images to the operator. At just 70 grams Black Hornet 4 can survive GPS-denied and contested environments, fly for more than 30 minutes, over three kilometers, and function in 25-knot winds and rain. Flight performance is augmented by advanced obstacle avoidance capabilities and other features.
The vehicle-integrated Black Hornet 4’s were delivered in 2025. The remaining systems will be delivered during 2026.
Teledyne FLIR has delivered more than 35,000 Black Hornet drones to military and security forces in over 45 countries. The award-winning Black Hornet is designed and built by Teledyne FLIR Defense in Norway.
About Teledyne FLIR Defense
Teledyne FLIR Defense has been providing advanced, mission-critical technology and systems for more than 45 years. Our products are on the frontlines of the world’s most pressing military, security and public safety challenges. As a global leader in thermal imaging, we design and build sophisticated surveillance sensors for air, land and maritime use. We develop the most rugged, trusted unmanned air and ground platforms, as well as intelligent sensing devices used to detect chemicals, biological agents, radiation and explosives. At Teledyne FLIR Defense we bring together this expertise to deliver solutions that enable critical decisions and keep our world safe – from any threat, anywhere. To learn more, visit us online or follow @flir and @flir_defense.
About Teledyne Technologies
Teledyne Technologies is a leading provider of sophisticated digital imaging products and software, instrumentation, aerospace and defense electronics, and engineered systems. Teledyne's operations are primarily located in the United States, the United Kingdom, Canada, and Western and Northern Europe. For more information, visit Teledyne's website at www.teledyne.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260201061637/en/
Contacts
Media Contact:
Joe Ailinger, Jr.
Teledyne FLIR Defense
Email: joe.ailinger@teledyne.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom